Azitra Business Summary

Azitra, Inc. (AZTR) is a clinical-stage biopharmaceutical company specializing in precision dermatology through a proprietary platform that leverages engineered proteins and topical live biotherapeutic products (LBPs). The company generates value primarily through research and development partnerships—most notably a joint development agreement with Bayer—and capital raises, while remaining largely pre-revenue as it advances its clinical pipeline. Azitra’s business segments are centered on its microbial library of approximately 1,500 bacterial strains, which are screened using artificial intelligence and machine learning to develop treatments for high-unmet-need skin conditions. Key assets include ATR-12 for Netherton syndrome, ATR-04 for EGFR inhibitor-associated rash, and ATR-01 for ichthyosis vulgaris. In the competitive landscape, Azitra contends with firms such as PellePharm, MatriSys Bioscience, and Naked Biome; it distinguishes itself as a pioneer in the use of genetically engineered commensal bacteria, specifically Staphylococcus epidermidis, to deliver therapeutic proteins directly to the skin. The company was co-founded in 2014 by Travis Whitfill, MPH, a serial biotech entrepreneur and former partner at Bios Partners, and Cain McClary, MD. The leadership team is currently headed by President and CEO Francisco Salva, who brings over 25 years of experience in biotech finance and was previously a founder of Acerta Pharma (acquired by AstraZeneca). Supporting the executive suite is CFO Norman Staskey and COO Travis Whitfill, who returned to a full-time operational role in 2023. Azitra’s board of directors features prominent industry figures, including Barbara Ryan, a former Deutsche Bank pharmaceutical research head and current Senior Advisor at Ernst & Young, and John Schroer, CFO of Alumis. The company has secured significant backing from notable investors such as Leaps by Bayer, Bios Partners, and KdT Ventures, reinforcing its position within the synthetic biology and medical dermatology sectors.